PearlERVoglerLBOkosAJ, et al. Lymphocyte precursors in human bone marrow: An analysis of normal individuals and patients with antibody-deficiency states. J Immunol1978; 120(4): 1169–1175.
3.
SmithCIBaskinBHumire-GreiffP, et al. Expression of Bruton’s agammaglobulinemia tyrosine kinase gene, BTK, is selectively down-regulated in T lymphocytes and plasma cells. J Immunol1994; 152: 557–565.
4.
Baecher -AllanCKaskowBJWeinerHL. Multiple sclerosis: Mechanisms and immunotherapy. Neuron2018; 97: 742–768.
5.
MontalbanXDouglasLAWeberMS, et al. Placebo-controlled trial of an oral BTK inhibitor in multiple sclerosis. N Engl J Med2019; 380(25): 2406–2417.
6.
ReichDSArnoldDLVermerschP, et al. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: A phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol2021; 20(9): 729–738.
7.
CrawfordJJJohnsonARMisnerDL, et al. Discovery of GDC-0853: A potent, selective, and noncovalent Bruton’s tyrosine kinase inhibitor in early clinical development. J Med Chem2018; 61: 2227–2245.
8.
EstupiñanHYBerglöfAZainR, et al. Comparative analysis of BTK inhibitors and mechanisms underlying adverse effects. Front Cell Dev Biol2021; 9: 630942.
